Cat. No. 4481
Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)o
Biological ActivityInhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 5 2634. PMID: 17121910.
Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 38 283. PMID: 18085662.
Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 206 1089. PMID: 19398755.
If you know of a relevant citation for this product please let us know.
Keywords: Ki 20227, supplier, Ki20227, c-Fms, macrophage, colony-stimulating, factor, receptors, M-CSFR, CSF1R, inhibitors, inhibits, osteolysis, osteoclasts
Find multiple products by catalog number
New Products in this Area
Selective and potent c-MET kinase inhibitorNBI 31772
High affinity insulin-like growth factor-I binding protein IGFBP inhibitorAPcK 110
Highly potent HGF/c-MET inhibitor; also AT4 antagonistAEE 788
Potent EGFR and VEGFR inhibitorXL 184
Potent VEGFR inhibitor; also inhibits other RTKsPKI 166 hydrochloride
Potent EGFR-kinase inhibitorASP 3026
Potent anaplastic lymphoma kinase (ALK) inhibitor
May 19 - 22, 2015